GT

Gunjan Tyagi

Active Director Director DIN 09575930
DIN 09575930 First appointment Apr 2022 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2022
Shareholding value •••• Premium profile

About Gunjan Tyagi

Data last updated:

Gunjan Tyagi is a Director at Xeno Pharmacare Private Limited (since 2022). The company operates in Chemicals. Xeno Pharmacare Private Limited reported revenue of ₹34.4 Lakh (FY 2024).

DIN 09575930
Primary Designation Director
Industry Chemicals
First Appointment 19 Apr 2022
Oldest Company Age 4 yrs
Largest company Xeno Pharmacare Private Limited · ₹34.4 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Xeno Pharmacare Private Limited U24290UR2022PTC013866
Director19 Apr 20222022₹34.4 Lakh (FY 2024)Active

Board colleagues of Gunjan Tyagi

NameDINCompanyDesignation
Neha09575929Xeno Pharmacare Private LimitedDirector

Directorship timeline

Open interactive timeline →
Xeno Pharmacare Private Limited
Premium access

Shareholding and investment profile for Gunjan Tyagi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gunjan Tyagi

Gunjan Tyagi currently holds 1 directorship: Xeno Pharmacare Private Limited (Director, since 19 Apr 2022, revenue ₹34.4 Lakh (FY 2024)).

Gunjan Tyagi was first appointed on 19 Apr 2022 as Director at Xeno Pharmacare Private Limited.

The current boards of Gunjan Tyagi's companies include Neha (Xeno Pharmacare Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available